Who are Zymeworks Inc.'s major customers?

Zymeworks Inc. (ZYME) key customers include: DAIICHI-SANKYO, Bristol-Myers Squibb Company, Bristol-Myers Squibb Company, Bristol-Myers Squibb Co, Bristol-Myers Squibb Co and 6 more. View the full customer network at chainsifter.com/chain/ZYME.

What sector is Zymeworks Inc. in?

Zymeworks Inc. (ZYME) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

ZYME Supply Chain: Zymeworks Inc. Suppliers & Customers

0Suppliers

11Customers

3Debt Items

20Related Chains

Zymeworks Inc. Suppliers

No suppliers on recordZymeworks Inc. has not yet been matched to upstream suppliers in our database, or is still being processed.

Zymeworks Inc. Customers

Ticker	Name	Confidence	Evidence
DAIICHI-SANKYO	DAIICHI-SANKYO	90%	The decrease in total revenue was driven mainly by the achievement of non-recurring clinical milestone payments in 2025 of $14.0 million and $3.1 million from GSK and Daiichi Sankyo, respectively
BMY	Bristol-Myers Squibb Company	85%	payments and royalties on potential future product sales we may receive. Importantly, these partnerships include predominantly non-target-exclusive licenses for any of our therapeutic platforms, so w…
BMY	Bristol-Myers Squibb Company	85%	Reciprocal relationship from BMY graph: Reciprocal relationship from ZYME graph: payments and royalties on potential future product sales we may receive. Importantly, these partnerships include predo…
BMYMP	Bristol-Myers Squibb Co	85%	Reciprocal relationship from BMYMP graph: Reciprocal relationship from ZYME graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from ZYME graph: Reciprocal relationship from BMYM…
BMYMP	Bristol-Myers Squibb Co	85%	payments and royalties on potential future product sales we may receive. Importantly, these partnerships include predominantly non-target-exclusive licenses for any of our therapeutic platforms, so w…
CELGENE-ALPINE-INVESTMENT-CO-LLC	CELGENE-ALPINE-INVESTMENT-CO-LLC	85%	payments and royalties on potential future product sales we may receive. Importantly, these partnerships include predominantly non-target-exclusive licenses for any of our therapeutic platforms, so w…
JAZZ	Jazz Pharmaceuticals plc	85%	: $ , 2022: $ ) in research and development expense and general and administrative expense accounts. As of December 31, 2024, the total amount contributed by ESPP participants and not yet settled is …
JAZZ	Jazz Pharmaceuticals plc	85%	Reciprocal relationship from JAZZ graph: Reciprocal relationship from ZYME graph: : $ , 2022: $ ) in research and development expense and general and administrative expense accounts. As of December 3…
BEONE	BEONE	80%	These decreases were partially offset by higher royalty revenue from Jazz and BeOne in 2026
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from ZYME graph: ne Medicines Ltd. (previously known as BeiGene, Ltd.) (“BeOne”): Milestone revenue Recognition of deferred revenue Dru…
JNJ	Johnson & Johnson	72%	ne Medicines Ltd. (previously known as BeiGene, Ltd.) (“BeOne”): Milestone revenue Recognition of deferred revenue Drug supply Development support payments Royalties Johnson & Johnson Innovative Medi…

Zymeworks Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
ZYME-DEBT	Debt stack $17.0M	90%	Market cache reports total debt of $17.0M.
ZYME-DEBT-13800	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2025-12-31.
ZYME-DEBT-13799	Warrants outstanding: 74	90%	xbrl warrant detail from xbrl 2023-12-31.

Zymeworks Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Zymeworks Inc..

Zymeworks Inc. Ownership

Holder	Name	Confidence	Evidence
ZYME-OWNER-ECOR1-CAPITAL-LLC	EcoR1 Capital, LLC	90%	13F overlay lists EcoR1 Capital, LLC as top holder; 221 tracked holders.

Zymeworks Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
BEAM	Beam Therapeutics Inc.	100.00	2
BNRG	Brenmiller Energy Ltd	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
BNR	Burning Rock Biotech Limited	100.00	2
BLLN	BillionToOne, Inc.	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
ANIK	Anika Therapeutics, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
WHWK	Whitehawk Therapeutics, Inc.	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
AXSM	Axsome Therapeutics, Inc.	100.00	2
AORT	Artivion, Inc.	100.00	2
AVBP	ArriVent BioPharma, Inc.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
EMMA	Emmaus Life Sciences, Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
CCEP	Coca-Cola Europacific Partners PLC	100.00	2

Zymeworks Inc. Supply Chain